Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Kaiser

Showing results (541-550 of 554) with videos related to

Pageof 56
Sort By:
Ophthalmology|September 22, 2016
Intravitreal Aflibercept for Diabetic Macular Edema: 148-Week Results from the VISTA and VIVID StudiesJeffrey S Heier, Jean-François Korobelnik, David M Brown, et al.
Ophthalmology. Retina|October 15, 2020
Patient-Reported Complications after Intravitreal Injection and Their Predictive FactorsMichael S Ramos, Lucy T Xu, Srinidhi Singuri, et al.
Ophthalmology|October 3, 2013
Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studiesUrsula Schmidt-Erfurth, Peter K Kaiser, Jean-François Korobelnik, et al.
Emerging Microbes & Infections|February 17, 2022
Infections with highly pathogenic avian influenza A virus (HPAIV) H5N8 in harbor seals at the German North Sea coast, 2021Alexander Postel, Jacqueline King, Franziska K Kaiser, et al.
European Journal of Cancer (Oxford, England : 1990)|December 3, 2014
Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: a double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programmeM Moehler, A Maderer, C Schimanski, et al.
Journal of Virology|November 4, 2024
A human monoclonal antibody neutralizing SARS-CoV-2 Omicron variants containing the L452R mutationSaskia C Stein, Guido Hansen, George Ssebyatika, et al.
Ophthalmology|July 23, 2015
Intravitreal Aflibercept for Diabetic Macular Edema: 100-Week Results From the VISTA and VIVID StudiesDavid M Brown, Ursula Schmidt-Erfurth, Diana V Do, et al.
Acta Ophthalmologica|April 7, 2022
Clinical impact of the worldwide shortage of verteporfin (Visudyne®) on ophthalmic careMarc J Sirks, Elon H C van Dijk, Noa Rosenberg, et al.
Ophthalmology|July 12, 2014
Intravitreal aflibercept for diabetic macular edemaJean-François Korobelnik, Diana V Do, Ursula Schmidt-Erfurth, et al.
Science Immunology|April 26, 2022
An ACE2-blocking antibody confers broad neutralization and protection against Omicron and other SARS-CoV-2 variants of concernWenjuan Du, Daniel L Hurdiss, Dubravka Drabek, et al.
Pageof 56

Showing results (541-550 of 554) with videos related to

Sort By:
Pageof 56
Ophthalmology|September 22, 2016
Intravitreal Aflibercept for Diabetic Macular Edema: 148-Week Results from the VISTA and VIVID StudiesJeffrey S Heier, Jean-François Korobelnik, David M Brown, et al.
Ophthalmology. Retina|October 15, 2020
Patient-Reported Complications after Intravitreal Injection and Their Predictive FactorsMichael S Ramos, Lucy T Xu, Srinidhi Singuri, et al.
Ophthalmology|October 3, 2013
Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studiesUrsula Schmidt-Erfurth, Peter K Kaiser, Jean-François Korobelnik, et al.
Emerging Microbes & Infections|February 17, 2022
Infections with highly pathogenic avian influenza A virus (HPAIV) H5N8 in harbor seals at the German North Sea coast, 2021Alexander Postel, Jacqueline King, Franziska K Kaiser, et al.
European Journal of Cancer (Oxford, England : 1990)|December 3, 2014
Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: a double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programmeM Moehler, A Maderer, C Schimanski, et al.
Journal of Virology|November 4, 2024
A human monoclonal antibody neutralizing SARS-CoV-2 Omicron variants containing the L452R mutationSaskia C Stein, Guido Hansen, George Ssebyatika, et al.
Ophthalmology|July 23, 2015
Intravitreal Aflibercept for Diabetic Macular Edema: 100-Week Results From the VISTA and VIVID StudiesDavid M Brown, Ursula Schmidt-Erfurth, Diana V Do, et al.
Acta Ophthalmologica|April 7, 2022
Clinical impact of the worldwide shortage of verteporfin (Visudyne®) on ophthalmic careMarc J Sirks, Elon H C van Dijk, Noa Rosenberg, et al.
Ophthalmology|July 12, 2014
Intravitreal aflibercept for diabetic macular edemaJean-François Korobelnik, Diana V Do, Ursula Schmidt-Erfurth, et al.
Science Immunology|April 26, 2022
An ACE2-blocking antibody confers broad neutralization and protection against Omicron and other SARS-CoV-2 variants of concernWenjuan Du, Daniel L Hurdiss, Dubravka Drabek, et al.
Pageof 56